7 results
Comparison of the additional blood pressure lowering effect of RFSD with that of the addition of spironolactone in patients with a persistant increased blood pressure despite treatment with three different antihypertensive agents.
Primary objectives: To assess the ability of dabrafenib + trametinib treatment to downsize melanoma tumor masses to enable R0-resection. Secondary objectives: Recurrence free survival; time-to-next treatment, overall survival.
The aim of the present study is to assess the contraceptive potential of the association of UPA 30 mg single dose and desogestrel 75 micrograms for 20 days. The study will also assess the potential possible interaction, (in terms of ovarian activity…
The primary objective of the study is:- To evaluate the pharmacodynamics effects on follicular growth and ovulation of one dose of 30 mg UPA taken before dominant follicle selectionThe secondary objectives are:- To determine the pharmacokinetics…
Primary: superiority of dabrafenib and trametinib combination therapy over dabrafenib and trametinib-placebo (dabrafenib monotherapy) with respect to progression-free survival (PFS) for subjects with advanced/metastatic BRAF V600E/K mutation-…
To demonstrate that a dose reduction of 20-33% of CYP3A4 metabolized tyrosine kinase inhibitors in patients expressing the CYP3A4*22 gene (rs35599367 C>T in intron 6) does not result in a lower exposure (Ctrough) than the wildtype group with…
Primary: overall response rate.Secondary: progression free survival, duration of response, overall survival, safety, tolerability, pharmacokinetics (PK).